Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus

Table 1

Tumors characteristics of metastatic site and matched primary breast cancer.

	Relapse		Primary tumor
	Site of biopsy	relapse characteristics	Primary tumor characteristics
Patient 1	liver	CDI ER90%, PgR 5%, Mib1 30%, HER2 1+	CDI ER100%, PgR60%, MIb1 25%, HER2 1+
Patient 2	breast	CDI ER60%, PgR 95%, Mib1 10%, HER2 1+	CDI ER98%, PgR98%, MIb1 15%, HER2 1+
Patient 3	liver	CDI ER40%, PgR30%, Mib1 40%, HER2 0	CDI ER98%, PgR70%, MIb1 30%, HER2 1+
Patient 4	liver	CDI ER100%, PgR 50%, Mib1 40%, HER2 1+	CDI ER100%, PgR80%, MIb1 25%, HER2 1+
Patient 5	chest wall	CDI ER 99%, PgR70%, Mib1 15%, HER2 0+	CDI ER 99%, PgR 70%, MIB1 15%, HER2 1+
Patient 6	liver	CDI ER 95%, PgR2%, Mib1 25%, HER2 1+	CDI ER 85%, PgR 70%, MIB1 35%, HER2 1+
Patient 7	lung	CDI ER 85%, PgR25%, Mib1 15%, HER2 1+	CDI ER 80%, PgR 60%, MIB1 25%, HER2 0+
Patient 8	breast	CDI ER 100%, PgR100%, Mib1 30%, HER2 1+	CDI ER 100%, PgR 100%, MIB1 35%, HER2 1+
Patient 9	liver	CDI ER 99%, PgR99%, Mib1 50%, HER2 1+	CDI ER 80%, PgR 60%, MIB1 25%, HER2 0+
Patient 10	liver	CDI ER 90%, PgR60%, Mib1 22%, HER2 1+	CDI ER 50%, PgR 50%, Mib1 10%, HER2 1+
Patient 11	liver	CDI ER 80%, PgR0%, Mib1 40%, HER2 1+	CDI ER 90%, PgR 50%, MIB1 25%, HER2 1+
Patient 12	skin	CDI ER 99%, PgR50%, Mib1 25%, HER2 1+	not applicable
Patient 13	bone	CDI ER 70%, PgR0%, Mib1 35%, HER2 0+	CDI ER 80%, PgR 60%, MIB1 25%, HER2 0+
Patient 14	bone	CDI ER 50%, PgR5%, Mib1 25%, HER2 0+	not applicable
Patient 15	liver	CDI ER 100%, PgR10%, Mib1 20%, HER2 1+	not applicable
Patient 16	lymph node	CDI ER 70%, PgR0%, Mib1 25%, HER2 1+	CDI ER 90%, PgR 80%, MIB1 8%, HER2 0+
Patient 17	liver	CDI ER 95%, PgR80%, Mib1 15%, HER2 0+	CDI ER 100%, PgR 100%, MIB1 15%, HER2 0+
Patient 18	lung	CDI ER 90%, PgR2%, Mib1 30%, HER2 1+	CDI ER 50%, PgR 65%, MIB1 25%, HER2 0+
Patient 19	lung	CDI ER 95%, PgR25%, Mib1 10%, HER2 1+	CDI ER 60%, PgR 10%, MIB1 25%, HER2 1+
Patient 20	lung	CDI ER 75%, PgR50%, Mib1 10%, HER2 1+	CDI ER 75%, PgR 20%, MIB1 15%, HER2 0+
Patient 21	bone	CDI ER 95%, PgR65%, Mib1 25%, HER2 1+	not applicable
Patient 22	bone	CDI ER 95%, PgR95%, Mib1 10%, HER2 1+	CDI ER 100%, PgR 85%, MIB1 3%, HER2 0+
Patient 23	liver	CDI ER 90%, PgR25%, Mib1 40%, HER2 0+	not applicable
Patient 24	lung	CDI ER 50%, PgR50%, Mib1 30%, HER2 1+	CDI ER 70%, PgR 50%, MIB1 25%, HER2 1+
Patient 25	lymph node	CDI ER 100%, PgR5%, Mib1 15%, HER2 0+	not applicable